Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Bio-Techne (TECH) opened a new manufacturing facility in Bristol, United Kingdom, expanding its production capacity for materials used in cell therapy development.
The 10,000-square-foot facility is fully operational and manufacturing small molecules under Good Manufacturing Practice (GMP), manufacturing quality standards. It contains five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to manufacturing and product handling. The Bristol operation complements Bio-Techne's recombinant protein manufacturing in Minneapolis and GMP capabilities in St. Paul. Bio-Techne says the expanded network supports customers from discovery through clinical development and commercial production.
Bio-Techne (TECH) shareholders approved the proposed acquisition by Merck KGaA, Darmstadt, Germany at a special meeting on September 23, 2026.
The vote adopts the definitive Merger Agreement, which Bio-Techne’s CEO says is expected to deliver substantial near-term cash value to shareholders and combine two complementary life science businesses across discovery, translational research, development, testing and commercial manufacturing. Final voting results will be disclosed in a Form 8-K filing with the SEC. The Hart-Scott-Rodino antitrust waiting period for the transaction expired on September 18, 2026, removing a key U.S. regulatory step. Bio-Techne continues to expect closing by late 2026 or early 2027, subject to remaining regulatory approvals and other customary closing conditions.
Bio-Techne (TECH) has opened a new Customer Experience Center in Düsseldorf, Germany, to give European researchers direct, hands-on access to its technologies and scientific expertise.
The flagship facility serves customers across the DACH region and the broader EMEA area, offering integrated workflows in protein biology, spatial biology, cell therapy, molecular diagnostics and analytical instrumentation. The center functions as a hub for demonstrations, interactive learning, and evaluation of complete workflows that can support translational research and clinical impact.
The site will also host workshops, technical training and thought leadership events, deepen collaboration with universities and emerging biotech companies, and is located in an energy-efficient refurbished facility with capacity for future expansion. Bio-Techne reports more than $1.2 billion in fiscal 2026 net sales and over 500,000 products used globally.
Bio-Techne (NASDAQ: TECH) reported progress toward its climate goals in fiscal 2026, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi). The SBTi approved targets to cut absolute Scope 1 and 2 emissions 70% by fiscal 2031 from a fiscal 2025 baseline and to have 81% of suppliers by spend set science-based targets by fiscal 2030.
According to Bio-Techne, market-based Scope 1 and 2 emissions fell 49% year-over-year, the company completed its first comprehensive Scope 3 emissions inventory, and renewable sources now provide 51% of its electricity. The Minneapolis headquarters moved to 100% renewable electricity, and renewable electricity procurement began for the St. Paul GMP facility.
Bio-Techne (NASDAQ: TECH) issued a correction to its recent dividend announcement, changing the shareholder of record date from August 17, 2026, to August 24, 2026. The Board approved a quarterly cash dividend of $0.08 per share, payable on August 28, 2026 to common shareholders of record on August 24, 2026; all other dividend details remain unchanged.
Bio-Techne (NASDAQ: TECH) declared a quarterly cash dividend of $0.08 per share for the quarter ended June 30, 2026. The dividend is payable on August 28, 2026 to shareholders of record as of August 17, 2026. The Board will review future dividends quarterly.
Bio-Techne (NASDAQ: TECH) reported fourth quarter FY2026 net sales of $321.2 million, up 1% reported and 3% organically. GAAP EPS rose to $0.35 from a loss of $0.11, while adjusted EPS was $0.52 versus $0.53. Full-year FY2026 revenue was flat at $1.2 billion, with GAAP EPS increasing to $1.16 and adjusted EPS to $1.93. GAAP operating margin improved to 20.7%, and adjusted operating income rose to $386.1 million.
Protein Sciences Q4 sales grew 2% (1% organic) with margin compression, while Diagnostics and Spatial Biology Q4 organic revenue increased 8% and operating margin improved to 11.2%. Bio‑Techne previously agreed to be acquired by Merck KGaA, Darmstadt, Germany, for $73 per share in cash, implying an enterprise value of about $11.3 billion. The company will no longer host quarterly investor calls due to the pending transaction.
Bio-Techne (NASDAQ:TECH) launched new R&D Systems AI-Engineered Designer Proteins to enhance advanced cell culture and cell therapy workflows. The expanded portfolio adds heat-stable fibroblast growth factors (FGF-4, FGF-7, FGF-8b) and cytokines (IL-3, hyperactive IL-15).
These engineered signaling proteins are designed to improve stability, activity, solubility, reproducibility, and scalability in stem cell, organoid, regenerative medicine, immunotherapy, and cell therapy manufacturing applications.
Merck KGaA, Darmstadt, Germany, agreed to acquire Bio-Techne (NASDAQ: TECH) for US$73 per share in cash, implying an enterprise value of US$11.3 billion, a 36% premium to Bio-Techne's one-month VWAP.
The deal, expected to close by late 2026 or early 2027, will be funded with cash and new debt, targets annual cost synergies of about EUR 140 million by year 3, and is expected to be immediately accretive to sales growth and EBITDA pre margin post-closing.
Bio‑Techne (NASDAQ: TECH) and Refeyn launched an integrated workflow that links MauriceFlex™ icIEF fractionation with TwoMP mass photometry for bispecific antibody and biosimilar analysis.
The four‑hour process directly correlates charge variants with size and aggregation using nanogram‑level samples, aiming to cut development risk and speed biosimilar manufacturing.